🟢 Hims Hers Health Inc is trading 5.6% up today as shares extend a rebound from Eucalyptus acquisition and dilution concerns

Hims Hers Health Inc is trading 5.6% up at $29.05, extending a sharp multi-day rebound as investors reassess the impact of its $1.15 billion Eucalyptus acquisition and GLP-1 transition strategy.

• The stock is recovering from a recent pullback driven by concerns over acquisition-related dilution and the company's long-term growth trajectory.
• Despite a mixed broader market, the move suggests strong dip-buying interest and continued momentum following heavy post-earnings volatility in May.
• Traders appear to be shifting focus back to the company’s core growth story as initial fears surrounding the Eucalyptus deal subside.